Litcius/Paper detail

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Gilles Salles, William G. Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd

2020The Lancet612 citationsDOIOpen Access PDF

Topics & Concepts

ObinutuzumabChlorambucilMedicineChronic lymphocytic leukemiaInternal medicineGastroenterologyOncologyLeukemiaCyclophosphamideChemotherapyChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentPhagocytosis and Immune Regulation